A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

Official title

A 52-week, Randomized, Double-blind, Double-dummy, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg), Parallel Group, Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI add-on to Maintenance Triple Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis.

Study identification

NCT ID

NCT04636814

Recruitment status

Terminated

Study type

Interventional

Phase

Phase 3

Lead sponsor

Chiesi Farmaceutici S.p.A.

Industry

Enrollment

3,973 participants

Conditions and interventions

Eligibility (public fields only)

Age range

40 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Jul 12, 2021 (Actual)

Primary completion

Dec 23, 2025 (Actual)

Completion

Dec 23, 2025 (Actual)

Last update posted

Feb 2, 2026

2021 – 2025

United States locations

U.S. sites

150

U.S. states

29

U.S. cities

105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 310 non-U.S. sites.